Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 28;33:e01864. doi: 10.1016/j.idcr.2023.e01864

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 1 — T1 sequences of contrast-enhanced MRI-scans of the brain; A: MRI at the time of presentation. A1: sagittal flair imaging. A2: sagittal T1 imaging with contrast agent. A3: coronal T1 imaging with contrast agent. B: MRI 4 weeks after treatment initiation. B1: sagittal flair imaging. B2: sagittal T1 imaging with contrast agent. B3: coronal T1 imaging with contrast agent. C: MRI 8 weeks after treatment initiation. C1: sagittal flair imaging. C2: sagittal T1 imaging with contrast agent. C3: coronal T1 imaging with contrast agent. D: MRI 12 weeks after treatment initiation. D1: sagittal flair imaging. D2: sagittal T1 imaging with contrast agent. D3: coronal T1 imaging with contrast agent. E: MRI 17 weeks after treatment initiation. E1: sagittal flair imaging. E2: sagittal T1 imaging with contrast agent. E3: coronal T1 imaging with contrast agent. F: MRI 30 weeks after treatment initiation. F1: sagittal flair imaging. F2: sagittal T1 imaging with contrast agent. F3: coronal T1 imaging with contrast agent.